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INTRODUCTION

A study of conformation in drug action can be approached from
two directions, (i) that of the drug, and (ii) that of the receptor.
Since the problem of elucidating the biologically active conformation
of drug molecules has been extensively studied and is very well re·viewed1'2, it should be equally productive to.explore the conformational
aspects of receptors.
Before a plausible model of conformational requirements at the
receptor level cru1 be developed, it is necessary to know something
about the nature of the biologic receptors.

Although structural

details for specific receptors are generally unknown and a fascinating
challenge for the medicinal chemist to study, the following considerations suggest that most receptors are lipoproteins with the ability
to interact with specific substrates at their active sites.

The known

characteristics of receptors can be summarized as follows:
a.

Receptors can bind with a wide variety of drug molecules,
suggesting a degree of conformational adaptability, a
characteristic of proteins.

b.

Some receptors exhibit a relatively high degree of stereospecificity, a property shared by enzymes.

c.

Most receptor-like substances which have been isolated have
been found to be proteoli.pid complexes, some of which may include phospholipids and prostaglandins if they are membranebound.

It seems pertinent to mention that the problems involved in the
isolation and characterization of drug receptors are formidable.

The

procedures employed in the extraction and purification of receptor-

2

like substances are laborious and tirn:;-conswning, and the isolated
material is, at best, only partially pure.

Moreover, the results

of drug-binding studies on such partially purified receptors are often
equivocal.

A review of the various approaches which have been taken

toward the isolation and characterization of drug receptors has been
recently published by Shirachi et al.3.

The authors have also

proposed a set of criteria which should be satisfied in order for a
drug receptor to be adequately characterized, and they have pointed
out that none of the approaches taken, thus far, satisfy all of the
suggested

criteria:~-

For example, the authors have stated that 11 no

adequate method is available for determining specificity of a labelling
ligand at the physiological level in order that it may be related
:rnE:!aningfully to specificity of interaction with isolated molecules 11 •
Notwithstanding the inherent problems and difficulties associated
with receptor isolation and characterization, progress is being made.
-

!

Especially notable is the very recent report of Lowney et al.

4

on

the partial purification of a proteolipid fraction of mouse brain
homogenate that binds opiate narcotics stereospecifically.

They used

- levorphanol and its L( +) enantiorn:;r dextrorphan as ligands.

Stereo-

specific binding was demonstrated by determining the distribution of
[ 14cJ levorphanol or [3riJ dextrorphan between an aqueous buffer layer
and an organic layer in the absence and presence of tissue extract.
Binding capacity was measured at aqueous phase levorphanol concentrations
from 10-7 to 10-6M, which reportedly correspond to concentrations
in brain water at which the drug produces analgesia and locomotor

3

activity in nontolerant mice.

A high-affinity stereospecific binding

component became saturated at a concentration which, :L.! brain water,
produces maximum pharmacologic effect in ·vivo.

Among the extracts

prepared from various tissues and brain regions, stereospecific
binding was shown to be localized predominantly in the rhombencephalic
portion of the brainstem.

This was considered to be significant since

sites of analgesic action are believed to be localized in those structures
surrounding the fourth ventricle.

The levorphanol-receptor complex

was isolated by means of gel colurm chromatography.

Virtually all

the radioactivity greater than the baseline emerged in a single sharp
peak and in a position which they believed to represent a stoichiometric
complex of high-affinity receptor sites with levorphanol.

The stereo-

specific binding of levorphanol was prevented, in a dose-dependent manner,
by the narcotic analgesic antagonist naloxone, but the authors did not
profess to tmderstand how this phenomenon relates to opiate antagonism
in vivo.

They speculated, as others have done, that agonist action must

be the result of a drug induced conformational change in the receptor.
The authors concluded by stating that it should be possible to determine,
with isolated receptors, whether opiate agonists cause a confornBtional
change and whether opiate antagonists can prevent it.
The hypothesis of induced conformational changes has been reviewed
by several

authors~' 6 For example, Koshland7' 8'9 suggested that the

active site of an enzyme does not need to be absolutely complementary
to that of the substrate, but after interacting with it, induction of
conformational changes can occur which might result in complementarity.
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Thus, it nBy be logical to assume on the basis of this hypothesis that
in combining with an enzyme the substrate indtwes. a change in its
conformation.

This results in an enzymically active orientation of

the catalytic groups.

The biological response resulting from such

a combination depends mainly upon the induction of an appropriate
conformational change.
Nachmanson10 suspected that drug molecules may induce conformational changes in the

rec~ptor.

He invoked the induced-fit-theory

to explain the action of acetylcholine on its receptors.
In 196Ll, Belleau11 proposed the macromolecular perturbation
theory of drug action.

He assl..ll'ned that drug-receptor complexation is

accompanied by a decrease or increase in free energy which presumably
induces confoT'I!'Btional changes at the receptor site.

This results

in the conversion of inactive species of the receptor into active
ones which catalyze reactions with drugs.

He assumed that drug-

receptor interactions should produce two general types of perturbations.
He envisioned that agonist-receptor binding causing a specific conformational perturbation would elicit a response,

while antagonists

or weak agonists causing a non-specific conformational perturbation
of the receptor would give no response or a weak response.
Recently, a new concept concerning the possible role of conformational isomerism in drug action has been proposed by Portoghese 1 •
His model envisages ligand-receptor association as depicted in Figure 1.
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Phases of receptor-ligand association cycle.

A =·High energy conformer of agonist
B = Low energy conformer of agonist
R = Receptor component
M = Macromolecular membrane subunit
AR-M= High energy drug.conformer-receptor assembly
BR*-M = Activated drug-receptor assembly
BWM'.· = Conformationally reorganized drug-receptor assembly
The salient aspects of this cycle are as .follows:
(i)

The agonist exists as an equilibrium mixture,

A~,

B, of a

preferred (B) and higher energy (A) conformer.
(ii)

The high energy conformer (A) has greater affinity for

R than B; therefore, it interacts with receptor component (R) faster
than B.
(iii)

Complex AR-M undergoes a conformational reorganization which

leads to a transfer of conformational free energy from ligand to R.
This process involves the decay of high energy conformer A to lower
energy conformer B with elevation of R to activated stateR*.
(iv)

Activated receptor assembly BR*-M undergoes conformational

reorganization to BR*-M'.

The energy of R* is considered to be dis-

sipated in the process of triggering the conformational reorganization
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of M toM'.

This is accompanied by a conformational change of R*

to RF, which is in an energy state similar to that of R.

Depolari-

zation of a nerve membrane is supposed to occur in the M' state.
(v)

Agonist-receptor-assembly complex

(BR~-M')

dissociates

to complete the cycle and lower energy conformer B is released from
the complex to re-establish equilibrium with A.
The most interesting aspect of this model to a medicinal chemist
interested in synthesizing rigid molecular analogs of drugs is that
it predicts that such analogs should be biologically inactive due to
conformational rigidity.
One of the ultimate goals in medicinal chemistry is to interpret
drug-receptor interactions in the terms of the conformation of the
drug and the conformation of the receptor.

Therefore, the elucidation

of the conformation of receptor-bound ligands is a great challenge
to the medicinal chemist and molecular pharmacologist.

One approach

to this problem is the design and biologic evaluation of conformationally
rigid molecules which may serve as models for the different conformers
of a single drug molecule.

Although little is known about the hydro-

cortisone receptor, a knowledge of the stereochemistry of receptorbound hydrocortisone should lead to a better understanding of the
hydrocortisone-receptor interaction.

The geometry of hYdrocortisone

is defined by the fused nature of the four rings ru1d the two-carbon
The c10-methyl, c11-hydroxyl, c -methyl, and
13
'17-beta-ketol side chain are above the plane of the ring and hydrogens
side chain at C-17.

at

c9

and c14 are below the plane of the ring (Figure 2).
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0

Figure 2.

Geometry of the Hydrocortisone rrDlecule.

It has been generally assumed that, for hormonal activity, the
surface of the steroid and receptor site must be complementary.

Accord·-

ingly, any alteration in this complementarity would affect the steroidreceptor interaction and, subsequently, the biological response.
Glucocorticosteroid-receptor interaction has been assumed to occur on
the beta-surface of the fused ring system. 12
Kier13 published the results of his molecular orbital calcMlations on a model compound which represented the D-ring and C-17
substituents of hydrocortisone and other 20-oxo-pregnane hormones.
He predicted the lowest- and the highest-energy conformations for the
20-oxo-17~beta,

21-dihydroxy model as represented by the Newman pro-

jections in Figure 3.

0

C-16

C-16

OH
A

Figure 3.

B

Conformations of C-17 ketol group of hydrocortisone
as projected along the C-17/C-20 bond.
A= Calculated highest energy conformer. B = Calculated preferred conformer.
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Accordingly, in the preferred conformer the carbonyl group projects
toward the beta face of the steroid molecule and the carbonyl oxygen
is nearly equidistnat between the C-16 and C-13 carbons.

The C-17 beta

ketal and C-17 alpha-OH groups are coplanar (as in Figure 3B).

In the

highest-energy conformer the carbonyl group projects toward the alpha .
face of the molecule, and the C-20/C-21 bond eclipses the C-17/C-13
bond.

It is satisfying to find that Kier's results agree reasonably
well with the results of Wellman and Djerrasi 14 , who applied optical
rotatory dispersion and circular dichroism measurerrents to the same
problem.

.

Kier's conclusions were further supported by the ir and nmr
studies of Cole and Williams. l5 Moreover, Cooper and Duax16 recently
.

studied the geometry of 4-chlorohydrocortisone by X-ray crystallography
and assigned the preferred C-16/C-20 bond conformation as represented
by the Newman projection in Figure 4.

0

13-C
C-16

Figure 4.

OH
Conformation of C-17 ketal group of 4-chlorohydrocortisone, as determined by X-ray crystallographic
analysis.l 6

In this conformation the dihedral angle C-16/C-17/C-20/0-20 is
approximately 30°, whereas Kier's model requires an angle of 60°.
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Kier's molecular orbital approach prompted us to study the
conformational specificity of hydrocorcisone for its receptor.

The

hydroxortisone .side chain has conformational freedom because of free
rotation about the C-17/C-20/C-21 single bonds.

It can, therefore,

assume different interconvertible conformations at the receptor site.
An

approach to the consideration of the possible complementary receptor

for hydrocortisone ultimately involves the elucidation of the conformation of the side chain of hydrocortisone which interacts with
the receptor.
This problem motivated us to undertake the syntheses of dioxolone
derivatives of the etianic acid, (ll~,l7oG-dihydroxyandrost-4-en-3one-l7/?-carboxylic acid) which might serve as models for the lowenergy conformation of hydrocortisone (Figure 5).

OH

0

I•.
c
-o

'··.o

0

H

A

OH
0

11

c-o·.

~CH3

0

4
Figure 5.

O

Dioxolone Derivatives as Models for a Low-energy
Conformer of Hydrocortisone.

\CH
3
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Dioxolone derivative

l was considered to be a reasonably good

model for the low-energy conformer of hydrocortis?ne since the scaled
molecular model of this derivative, as constructed from Courtould
atomic models revealed a striking similarity to hydrocortisone with
respect to the spatial relationships of its three oxygen functions
in the dioxolone ring and the corresponding oxygen functions in the
17-alpha-ketol group of hydrocortisone.

Dioxolone derivative 4.. was'in-

tended to serve primarily as a reference compound for the chemical
characterization studies, although a

con~arison

dioxolone derivative· '3'-~ might be interesting.

of its activity to that of

The presence of the

_ge~dimethyl groups in the no. 2 position of the dioxolohe ring could
be obstructive to plasma protein or receptor binding.

On the other

hand, the two methyl groups could contribute significantly to hydrophobic
binding.

However, the use of either of these derivatives as a model

for hydrocortisone might be criticized on the grounds that it lacks
the C-21 and 17-alRha-hydroxyl groups which are present in hydrocortisone,
since these OH groups are known to contribute significantly .to the
anti-inflammatory activity of hydrocortisone. 1 7 It would not be
surprising, therefore, if the dioxolone derivatives shoQld show a
relatively low order of activity as compared to hydrocortisone.

If

this should be the case then the results might lend support to the
hypothesis that the 17-alRha- and 21-hydroxyl groups in the structure
of hydrocortisone serve as hydrogen-bridge donors in the steroidreceptor interaction.
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In connection with the role of the 17.:.alpha- and 21-hydroxyl groups
as possible hydrogen~bridge .donors the protein bindii'1g studies of Eger
et al. 18 tend to support this hypothesis. These workers have investigated the types of non-covalent, dissociable bonds possible in
the

17-~

derivatives.

side chain of adrenocorticoids and certain related pregnane
11le binding of various steroids, including hydrocortisone,

to the hurrnn plasma proteins transcortin, alpha·-1-acid glycoprotein,
and serum albumin was evaluated by determining association constants
'

for the· steroid-protein complexes and by observing the shifts which
occurred in the infrared absorption frequencies for the carbonyl and
hydroxyl groups upon complexation.

Their data led them to speculate

that the 17-beta-ketol group of hydrocortisone functioned solely as a
proton donor when binding to plasma proteins.

Although the role of

functional groups in the binding of a steroid to a carrier protein is
not necessarily the same in the steroid-receptor interaction, the fact
that the authors found a correlation between glucocorticoid activity
and hydrogen-bridge donor capacity for various glucorticoids, including
hydrocortisone, led them to conclude that the degree of specificity and
potency shown by these steroids is dependent, at least in part, on
their binding affinities for transport proteins and that these steroids
may also show similar binding affinities for the receptor proteins .
.It should be of interest. to compare the protein binding affinities
of these dioxolone derivatives to those of the. glucocorticoids which
Egar et al. studied.

Such a comparative study would appear to be

a good test of their hypothesis that the 17-beta-ketol group of hydro-

12

cortisone and related glucocortocoids functions primarily as a hydrogenbridge donor in plasma protein.binding and steroid-receptor interactions.
We suggest that this ramification of our studies should be the subject
of a future investigation.
The design of a comparable steroid derivative as a conformationally
rigid model of a high energy conformer of hydrocortisone is difficult
to envision.

Such a model should have the following characteristics:

(l} the carbonyl group should be bonded to C-17 of the steroid ring

system and it should have the beta configuration as in dioxolone
derivatives } and

~;

(2) unlike the dioxolone derivatives } and

~'

the carbonyl group must be projecUng from the alpha face of the steroid
molecule; (3) the remaining two oxygen functions should be members of
a heterocyclic ring, preferrably a dioxolone ring, and bear spatial
relationships similar to those of the oxygen functions in dioxolone
derivatives } and

~;

and ( 4) the three oxygen functions should lie

approximately in the same plane, a condition which is approached very
closely by the spiro fusion of the five-membered dioxolone ring to
the Dring of the steroid at C-17.

We have considered two possibilities,

neither of which satisfY all of the requirements outlined above (Figure 6).
Dioxolone derivative 2 is the epimer of dioxolone derivative },
and it should be possible to synthesize this compound from the steroid
acid,

"llfi-,

~-dihydroxyandrost-4-en-one-17oG-carboxylic

derived from the corresponding cyanohydrin.

acid,

However, as a model for

a high-energy conformer of hydrocortisone it suffers from the fact
that the carbonyl group has the alpha configuration.

Therefore, we

would anticipate that this derivative will show little, if any, antiinflammatory activity.

On the other hand, if the C·-20 carbony1 group
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0

Figure 6.

Dioxolone Derivatives considered as possible models
for a high-energy conformer of hydrocortisone.
of glucocorticoids is relatively unirrportant insofar as bindj_ng to plasma
proteins is concerned then it would be of interest to corrpare the protein
binding affinity of this dioxolone derivative to those of the glucocorticoids studies by Eger et a1. 18
Dioxolone derivative £perhaps more closely represents a highenergy conformer of hydrocortisone but also fails to meet the requirement of a carbonyl group being bonded to C-17 with the beta
configuration.

Conceivably, this compound could be synthesized by

reacting the appropriate 17-keto steroid with glycolic acid, leading to
a mixture of diastereomers which would have to be separated.

In view

of the stereospecificity of the cyanohydrination of 17-keto steroids,
we might anticipate that the desired diastereomer, dioxolone derivative
£, would be the minor product of the reaction.
Finally, we decided to undertake the synthesis of dioxolone
derivative 2 as a possible high-energy conformation model of hydrocortisone.

We suggest, however, that the synthesis and pharmacologic evaluation

of dioxolone derivative 6 should be the objective of another investigation.

GLOSSARY OF
CHEIVIICAL NAMES, STRUCTURES AND ABBREVIATIONS

The following structures will be of concern in this thesis:
Number l.
11p ,l75-dihydroxyandrost-LI-en-3-one-l7P.-carboxylic acid (l).

Abbreviated Narne:
l7p-acid

COOH

Number 2 ..
ll~ ,17@-dihydroxyandrost-LI-en-3-one-17~-carboxylic

Abbreviated Name:
l7cl-acid

acid (.?_).

OH

0

Number 3.
(4'R)-spiro[ll)9-hydroxyandrost-4-en-3-one-l7,4'-(l' ,3'-dioxolan5'-one)] (3).
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Nwrber 4.
( 4 'R)-~..l:!.Q[llp-hydrox.ya...'ldrost-4-en-3-one-17 ,4 1 ( 2' ,2'-dimethyl~3 '-dioxo1an-5 1 -one)

] ( 4) ·.

Number 5.
(4 1 S)-spiro[11~-hydroxyandrost-4-en-3-one-17,4 1 (1 1

5'-one)] (5).

/

,3'-dioxo1an-

CH2'

.. - -~ c /

0

If
0

Ntmber 6.

0

(4'R)-~[11~-hydroxyandrost-4-en-3-one-~7'

4-one)] (6).

o-c~°

,5'-(1' ,3-dioxo1anCH

/2

. ., -- ., .. 0

NWTJber 7.
l:-py:droxycyc1opentane ca.rbo,xy1ic acid (7).
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Nurrber 8.
Androst-4-ene-3,11,17-trione (8).
0

0

Number 9.
'

.

(9).
- 3-pyrro1idinoandrosta-3,5-diene-11,17-dione
•-'
./
0

Nurrber 10.
17!?f. -cyano-17~-hydroxy- 3-pyrro1idinoandrosta-3, 5-diene-11-one (1Q) •

OH

\
(

17

Nwnber 11.
17o{,-cyano-11/3, 17 j3-dihyc1roxy~3~pyrrolidinoaJ1drosta-3,5-diene (ll).
OH

spiro-4'-(1' ,3'-dioxo1an-5'-one) (12).

Nurrber 13.
p-to1uenesu1fonic acid (13).
Abbreviated Name:
r:l1 s0H

Number 14.
Trif1uoromethanesu1fonic acid (14).
Abbreviated Name:
TFMSA

DISCUSSION

The present study embraces the synthesis and biologic evaluation
of conformationally constrained model of hydrocortisone with the
objective of acquiring information about the conformational specificity
of the hydrocortisone receptor.

With this objective, the syntheses of

dioxolone analogu.es of 11.§ , 17~-dihydroxyandrost--4-en- 3-one--17~
carboxylic acid (]) and the epimeric 17~-carboxylic acid ( 2) were
designed as outlined on the following page.
It was thought logical to synthesize the model compound 12 in which
cyclopentane represents the D-ring of the steroid.

It was hoped that

the spectral data on this ,compouriQ; VJould be useful in the characterization of the dioxolone-type derivatives of the steroidal alphahydroxy acicts. 25
Attempts were made to dioxolate

1-hydroxycyclopentanecarbo~Jlic

acid, using different acid catalysts. 19
HO

/

COOH

6

1

2
0(5
0

)

"-cH

12

The use of p-toluenesulfonic acid (TsOH) yielded only starting
material, while the use of HClO 4 gave a gum-cy oily mixture which could
not be resolved. Column chromatography of the mixture over silica
gel yielded 30 fractions which were monitored by the means of ir
spectroscopy.

Their spectra of fractions 20 through 30, eluted
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Synthesis of (4 1R)-Dioxo1one

e

Jl..nalogues of 17 -acid
CH20H

I

C=O

0

Hydrocortisone

[0]

0

HI0

4

1

0

4

20

Synthesis of (4'S)-Dioxolone
Analogue of l'To(- acid

0

0
0

8

0

I
H

H

o+

3

0

H·CHO
OH

0

HOH

OH

OH
C;N
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with 1:1 benzene-chloroform, showed absorption at 1795 cm- 1 (lactone

;c=O)

and the disappearance of carboxylic carbonyl indicating that dioxolation
might have occurred.

The lack of workable quantities of these eluates

prevented further characterization of the product.
For the synthesis of compound 1, hydrocortisone was selected
as the starting material.

It was selectively oxidized with periodic

acid yielding 11~,17~-dihydroxyandrost-4-en-3-one-17~-carboxylic
acid. 20 This intermediate was characterized by ir absorption at
1730 cm-l for the carboxylic carbonyl group. 21 , 22 The nmr spectrum
exhibited chemical shifts for the angular methyl groups in deuterated
d.ilrethyl sulfoxide which closely agreed with the calculated values from
Zurcher's table 23 , 24 shown in Table I.
TABLE I

Zurcher's Additive Constants for
C-18 and C-19 Methyl Protons in Steroids. 23
C-10 (methyl)
ppm

5o{,, 14 o(,-androstane (Reference compound)
-

-

18 17

11

C-13 (methyl)
ppm

0.692

0. 792

0.058
0.242
0.025
0.042

0.200
0.258
0.008
0.008

1.06
0.94
0.12

1.27
1.26
0.01

16
15

2
3

3 oxo-4-en-system
llf3-0H
l'{j-COOH
17E_C,-OH

(Substituents present within the reference)
Calculated
Observed
Difference
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This intermediate (!) was subjected to dioxolation with paraformaldehyde in the presence of three types of acid catalysts.

With the

use of TsOH only the starting material coUld be recovered.

The

variation of conditions, by prolonging the time of reaction, did not
show encouraging results.

The reason for this failure might be· the

poor solubility of the steroidal acid in the benzene and toluene.
Lewbart et a1. 25 recently found that perchloric acid is quite
effective for the acetonation of the 17, 20-glycol in the steroid
series.

They reported that ir and nmr spectral data make it possible

to distinguish between etiodioxolones* and 20, 21 dioxolones of the
steroidal alpha-hydroxy acids, as given in the following table.
TABLE II

Spectral Data for Etiodioxolones and .20;21..,.dioxolones .....
IR bands (cm-1)

lactone
Etiodioxo1ones

Dioxolones

'·c-o
-

nmr ppm
C-13 Me
C-10 Me

/

ll{J -OH

1137-1136
(C-0 stretching
of alcohol)

1782

0.77

0.099

11-keto

938- 936
(CH 2 bending)

1795

0.60

0.088

1130-1120
(C-0 stretching
of alcohol)

1785

0.62

0.090

889- 879
. ( CH2 bending) .

1790

0.64

0.084

20,21-dioxolones
11{1- OH
11-keto

* Etianic

acid has COOH ( o/, or f3) at the C-17 carbon atom of the steroid
nucleus. Etiodioxolones are1actonic derivatives of 17 o(,-hydroxy
etianic acid.
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The examination of ir spectra revealed that the carbonyl and
methyl group stretching bands of 20, 21-dioxolones occur at a lower
frequency than those of etiodioxolones.

In the nmr spectra the proton

resonances for the C-19 methyl fall within 0.088-0.090 ppn1 because
they are farther removed from the dioxolone ring.

The C-18 methyl

resonance appears downfield due to the closer approach of the C-18
methyl group to the confornlationally fixed dioxolone ring. 25
The procedure of Lewbart et al. 25 using HC10 4 and paraformaldehyde,
was applied to the dioxolation of 11J3 , 17c<,-dihydroxyandrost-4en-3-one-17f -carboxylic acid.

The tlc of the reaction m:Lxture

showed s:Lx spots, wh:Lch are alphabet:Lcally des:Lgnated ·A,B,C,D,E,
and F.

The examination of the chromatogram in UV light after
spraying with 50% H2so 4 26 showed substances B,C, and D as green
fluorescent spots. The column chromatography of the mixture over silica
gel yielded substance D corresponding to compound .J in a chromatograph:Lcally pure state.

The ir spectrum showed lactone carbonyl

absorption.
The nmr spectrum of

l in deuterated dimethylsulfoxide, using

TMS as an internal reference showed peaks at 1.44, 1.74, 4.42, 5.64
and 5.78 ppm corresponding to the C-18 and C-19 methyl groups, the
11~-0H

or

11~-H,

respectively.

vinylic-H, and methylene protons (dioxolone ring)

The assignment of 4. 42 ppm to either the 11{3 -OH
.

-

proton or the lloC-H proton is tentative since a D20 exchange was not
undertaken.

In order to rationalize the correct chemical shift of the methylene
protons in the nmr spectrum of the (4'R)-dioxolone, which appeared
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close to that of the vinyl proton, an analogous approach was made.
The assignJnent of 5. 64 ppm to the v-inylic proton is based partly
on the studies of Sharma et al. 27 who found the chemical shift ·for
this proton to appear consistently at 5.66 ppm for their spirooxazolidine steroid derivatives, e.g. (5'5)-spiro[4-androsten-3-one17,5'-(2,2'-dimethyloxazolidine)], in deuterated d:irrethylsulfoxide.
Our nmr spectra of hydrocortisone and the compound (]) showed a singlet
at about 5.6 ppm in the same solvent.
The assignment of 5.78 ppm to the methylene protons of the
dioxolone ring in our spiro dioxolone steroid derivatives is supported
by the fact that no peaks were observed at this frequency in the nmr
spectrum of

(4'R)-spir?[ll~-hydroxyandrost-4-en-3-one-17,4'-(2',2'

dimethyl-l' ,3'-dioxolan-5'-one)].
Attempts were made to reduce the conjugated double bond of compound
· 1 in order to confirm the assignment of the vinylic proton in the
'lbe reduction of l with NaBH 4 in methanol and isoprop28
.
anol did not give the desired products.
The recovery of the

nmr spectrum.

Compound l was ~thE=m ·subjected to NaBH -reduction
4
2
in the presence of anhydrous pyridine. 9 The oily residue was ex-

starting material was 90%.

tracted with ether and chloroform.
product (m.p. 130-132°C).

The ether fraction yielded one

Its ir spectrum showed the absence of

absorption between.l650-16oo cm-l and the presence of hydroxyl
absorption at 3600-3550 cm-1 . Further evidence for the reduction
of the ring A chromophore was the absence of UV absorption (in
alcohol) between 230 and 290 mfl'.

rrl1e nmr spectrum was determined
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at 60 MHz in deuterated dimethylsulfoxide, but due to the small size
of the sarnp1e the signals v.1ere too weak to permit U.'lequivocal assignments
to be made.
Trifluorornethanesulfonic acid, a stronger acid than HCl0 4 , was
found to be a very effective catalyst for the dioxolation of the steroidal, . . alpha-hydroxy acids.

The relative effectiveness of the two

catalysts was assessed by comparing the results of tlc.

TFJVJSA was found

to be quite selective as it favors predominantly the formation of one
product.
The dioxolation of (]) was performed using TFJVJSA.

The compound

(!_!) was found to be the major product which was purified by co1wnn
chromatography over silica gel.

The spectral data and melting point

2
agreed with the previously reported data. 5
IJ.be partial synthesis of 11 {3 , 17 fJ -dihydroxyandrost-4-en-3one~17~-carboxylic

acid has been achieved, starting from androsterone.

The compound (1) was enaminated with pyrrolidine. 30 ·The resulting
enamine (_§) was characterized by its i r and nrrrr spectra.

The ir

absorption at 1610 cm-l ( C=C) and the disappearance of absorption
at 1640-1630 cm- 1 due to conjugated carbonyl indicated that enamination
had occurred.
This enamine intermediate was subjected to cyanohydrination with
acetone cyanohydrin.3l The gummy product was chromatographed over
silica gel yielding

2.

which was selectively reduced with lithium

2
tri-t-butoxyaluminium hydride for the reduction of the ll-keto group. 3
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Repeated fractional crystallization of the syrupy product yielded
10.

The appearance of hydroxyl absorption at 3500 cm-l indicated

that reduction of the 11-keto group might have occurred.
Attempts were made to hydrolys.e the 17-§lpha-nitrile group by
acid- and base-catalysed hydrolysis.33,3 4 Their spectrum of the acid
and base hydrolysate indicated that partial hydrolysis had occurred.
Further variation of conditions by increasing the duration of

hydl~olysis

did not give encouraging results.
The preliminary biological evaluation of 1 and 41! indicated
that they are less active than hydrocortisone.
chain of hydrocortisone is composed of an

Since the 17-beta-side

alph~-ketol

group

(c 20-c 21 )

it might be anticipated that intramolecular hydrogen bonding (Figure 7)

would occur between the C-20 carbonyl and hydroxyl groups at C-17
21 CH

and C-21.

I

- 0 - JI
2 •..• / '
•'

20 C=O,
I'

.

··.. .

\'

HO

Figure 7
However, recent spectroscopic studies (ir and nmr) do not support this
postulation. 15 It would be worthwhile to mention that recent studies
on the role of the 17-beta-side chain of hydrocortisone in protein

binding18 strongly suggested that the ketol group at C-17 is a fairly
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good proton donor, but that the C-20 carbonyl is a weak proton acceptor.
The weak biological activity of } supports the cux·rent hypothesis that
the hydrocortisone receptor site may act as a proton acceptor for the
17-beta ·Side chain of hydrocortisone.

The conformational rigidity

and lack of cl7 and c21 hydroxyl functions in the dioxolone analogue
may also be responsible for the low anti-inflammatory activity.

CHEMICAL METHODS

General Techniques. Elemental analyses and molecular weights were determined by
Galbraith Laboratories, Inc., Knoxville, Tenn.

Melting points were

determined in glass capillaries with a Thomas-Hoover apparatus and
are uncorrected.

Infrared spectra (ir) were obtained on a Perkin-

Elmer Model 457 Spectrophotometer in KBr pellets.

Nuclear Magnetic

Resonance (nmr) spectra were determined at 100 MHz with a JEOL MH-100
instrument using TMS as the internal standard.

The chemical shifts

are recorded as parts per million.
Thin layer chromatography (tlc) was performed on silica-gel
G using the solvent systems of acetone-benzene ( 1·: 4) and ethyl acetate.
The spots were visualized by spraying with 50-75% H2so 4 and heating
at 100°C for 10-30 --min.
The column chromatography was performed on silica gel (Baker) .
Sources of all chemicals used in the syntheses are listed in
Appendix A.

Attempted Synthesis of CyclopE:mtane: spiro.,.4:'.:-{1'.·,3'.:..~oxolan:..sr~one) (11).
Procedure A:

To a solution of 500 mg of

l

in 50 ml of anhydrous benzene,

500 mg of paraforrrBldehyde and 18 mg of TsOH were added.

This mixture

was subjected to azeotropic distillation for 13 hrs, but no reaction
occurTed.

The recovery of the starting material was 98%.

The pro-
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1ongation of time from 13 hrs to 72 hrs did not. give the desired results.
Procedure B:

To a solution of 500

~

of

l in 250

ml of dimethoxy-

rrethane was added 0 . 5 ml of HClO 4 ( dimethoxymethane is the source of
formaldehyde in this case).

The solution was allowed to stand at

room temperature for 6 hrs.

The solvent was removed at room temperature

in vacuo and the residue was partitioned between methylene chloride
(50 ml) and water ( 25 ml) .

The organic layer was washed three tirres

with JN NaHco
Na2so L!.

and five times with water and then dried over anhydrous
3
The product was then evaporated to dryness, yielding 200 mg

of brownish oily residue.

Attempts to resolve this mixture by tlc in

various solvent systems did not give satisfactory results.

Therefore,

it was chromatographed over silica gel yielding 30 fractions.

The ir

spectra of fractions 20 through 30 eluted with benzene-chloroform (1:1)
showed absorption at 1795 em-l (lactone ) C==O) and disappearance
of absorption due to carboxylic carbonyl, which suggested that dioxo1ation may have occurred.

The lack of workable quantities prevented

further purification and characterization.
'

Synthesis of llJ!, 17 <X, -dihydroxyandrost-4-en-3..,.one-17 P -carboxylic
acid. (1)
Hydrocortisone ( 185 mg) was dissolved in dioxane ( 21 ml) and mixed
with periodic acid (185 mg in 8 ml water).
to stand at 18-20°C for 16 hrs.

This mixture was allowed

The solvent was removed at room

temperature in vacuo and the residue was taken up in chlorofonn, washed
with water and extracted with 1!:!_ NaHco .
3

Acidification of the sodium

.
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bicarbonate extract with

~HCl

gave solid (115 mg, 62%) which was
crystallized from ethyl acetate [mp 241-245°C, Lit, 20 235-245°C];

ir 3490 cm-l (bonded -OH), 1730 cm-1 (carboxylic C=O), 1630 (conjugated
C=O), nmr (DMSO-d6) ppm 0.94 (18-Me), 1.26 (19-Me), 5.62 (C-4 vinylic H).

Anal. Calcd for c20H28o (350.00):
5

Found:

Mol. wt. Calcd. for

c20H28o 5 :
Found:

350
351

C, 68.74; H, 8.36
C, 65.31; H, 8.19.
(osmometry)

NaBH 4 Reduction of 17f3 -Acid. Procedure A:

A solution of 50 mg of lin anhydrous methanol (25 ml)

containing 0.5 g of NaBH 4 was stirred for 3.5 hrs at room temperature.
Water (10 ml) was added and the resulting suspension was acidified
with

~HCl

and extracted repeatedly with ether.

The ether layer

was washed three times with 0.2N HCl and five times with water.
It was dried over anhydrous Na2so 4 and evaporated to dryness in vacuo.
The semi-crystalline residue, after crystallization from ether, gave
23

mg

of crystalline material which was found to be identical to the

starting material (240-246°C).
Procedure B:

A solution of 1 (100 mg) in freshly distilled isopropanol

(60 ml) containing 1 g of NaBH4 was stirred for 3.5 hrs at room temperature.
The solvent was removed in vacuo and water ( 60 ml) was added to the
residue.

The suspension was then acidified with lN HCl (pH 3-4) and

the aqueous layer was extracted repeatedly with ether. The ethereal
layer was dried over anhydrous sodium sulfate and the solvent evaporated.
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The semi-crystalline residue was crystallized from acetone yielding
89 mg of crystalline material which was fou1·1d to be identical to the
starting material (mp 242-246°0).
Procedure 0:

A solution of

l

(50 mg) in anhydrous pyridine (2 ml)

containing 55 mg of NaBH was stirred at room temperature for 6. 5 hrs.
4
The sol vent wa..s removed in vacuo and water ( 10 ml) was added to the
residue.

The resulting suspension after acidification with

1Ji HOl,

was repeatedly extracted with ether and chloroform successively.
Both organic layers were successively washed three times with

0.2~

HOl and water (until neutral), and dried over anhydrous Na2so .
4
Fractional crystallization of the residue with ether- petroleum ether
gave 8 mg of material (mp 130-132°0).

It was found to be chromato-

graphically pure (tlc) using ethylacetate as a solvent system and
spraying with 75% H2so 4 and heating for 30 min.

The ir spectrum of

this material showed absorption between 3600~3550 cm-l (non-bonded
OH) and the absence of absorption between 1799-1600 cm-l, indicating
that reduction of the conjugated carbonyl might have occurred.

It was

further supported by absence of UV apsorption between 230-300 mj.b using
alcohol as the solvent.

Synthesis of (4 1 R)-spiro[ll#-hydroxyandrost-4-en-3-one-l7,4'-(1',3'dioxolan-5'-one)]. (3) Procedure A:

Dioxolation of

I

(200 mg) was carried out at room temperature

with paraformaldehyde ( 200 mg) in 200 ml of dioxane using 0. 5 ml of
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perchloric acid (70%) as·a catalyst.
for 6hrs.

The mixture was allowed to stand

The mixture was concentrated in vacuo and the oily residue

was partitioned between methylene chloride (10 rnl) and water (10 rnl).
The organic layer was washed twice with 1N NaHC0 , three times with
3
water, and finally dried over anhydrous soditun sulfate. The dried
organic layer was concentrated and the oily residue was chromatographed
over silicagel.

Elution with ethyl acetate-benzene (1:1) yielded

120 mg of semi-crystalline material which was crystallized from
acetone-ether to give crystalline material (100 mg, 50%), rnp 234-236°C.
Anal. Galcd. for c

H o ·l/2 H 0 (370.00)
21 28 5
2

C, 68.27;

H, 7.91

Found:

c, 68.47;

H, 7.69.

Mol. wt. Calcd. for c 21H o ·l/2 H20 (370.00)
28 5
Found:

361

(average of 4 deter-

minations by osmometry)
ir 3600 cm-l (OH-norillonded), 3000-2900 cm-l (CH stretching), 1785 cm-l
(lactone ).c=a), 1670 cm-l (conjugated )c=O); nrnr (DMSO-d )
6

ppm l. 44

(18-Me), 1.74 (19-Me), 4.42 (ll~..:.oH or 11«>(,-CB_), 5.64 (4[-v:Lnylic),
5. 78 ( CH -dioxolone ring) .
2

1. ( 200

Procedure B:

To a solution of

rng) in 200 rnl of dioxane were

added 200 mg

of paraformaldehyde and 0. 25 rnl of TFMSA.

was then allowed to stand for 6 hrs at room temperature.

The mixture
It was

concentrated in vacuo and processed in a manner similar to that in
procedure A above.

The column chromatography of the mixture over

silica gel yielded 108 rng of crystalline material (rnp 234-236°C),
which was found to be identical to the product obtained by procedure A.
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Synthesis of ( 4 'R)-?piro[ll/3 -hydroxyandrost-4-en-3-one-17 ,4 '-(2' ,2 'I

dDnethyl-1',3'-dioxolan-5'-one)]. (4)To a solution of l (200 mg) in 200 ml of acetone was
added 0.5 ml of 70% HCl0 4 . 25 After standing 6 hrs at room temperature
the solution was concentrated to a small volume (about 5 ml) in vacuo,

Procedure A:

and partitioned between methylene chloride and water.

The organic

layer was successively washed with lN NaHco and water. The oily
3
residue obtained after removal of solvent was chrornatographed over
silica gel.

Elution with ethyl-acetate-benzene (1:1) gave 128 mg

of crude material which was crystallized from acetone-ether (mp 223-225°C),
yielding crystals (120 mg, 60%); ir 3450 cm-l (bonded OH); 3000~2900 cm-l
(C-H stretching) 1790 cm-l (lactone) C=O); 1640 cm-l (conjugated
C=O); 1390, 1380 cm-l (ge~dimethyl), nmr (CDC1 ) ppm 1.44 (18-Me),
3
1.26 (19-Me) l.lLI (dioxolone methyls), 4.42 (llf3- OH), 5.64 (C-4
vinylic H).
Procedure B:

To a solution of l (100 mg) in 100 ml of acetone was

added 0. 25 ml of TFMSA.
temperature for 6 hrs.
Procedure A above.

The mixture was allowed to stand at room
It was then processed as described in

Column chromatography of the mixture over silica

gel yielded crystalline material (78 mg, 78%) which melted at 223225°C.

The ir spectrum of this product was identical to that of

the product obtained in Procedure A.

Synthesis of

3~~rrolidinoandrosta-3,5~diene-11,17~dione.

(~)

-

Pyrrolidine ( 1. 45 g) was added to a hot solution of androst4-en-3,11,17-trione (3.8 g) in 110 ml of methanol under a nitrogen
atmosphere.

The solution was allowed to cool slowly at room temperature.

The crystals (3.0 g, 78%) were filtered off, washed with cold methanol,
and dried. The crystals decomposed above 186°C [Lit 30 , above
186°C]; i r 2890 cm-l (C-H stretching), 1740 and 1700 cm-l (17- and

ll~keto group), 1610 cm-l (C=C); nmr (CDC1 ) ppm 0.87 (18-Me), 1.24
3
(19-Me), 5.64 (C-1+ Vinylic !i), 4.62 (C-6 Vinylic

g_).

Synthesis of 17 o(, -cyano-17 fJ -hydroxy-3-pyrrolidinoandrosta-3, 5diene-11-one. (10) acetone cyanohydrin.

Compound~

(2 g) was dissolved in 5 ml of anhydrous

This solution .was re fluxed for one hour.

After

standing at room temperature for 2 hrs, the mixture was diluted
with water ( 200 ml) and extracted five times with ether.

The ethereal

layer was washed with water, dried over anhydrous Na2so 4, filtered,
and concentrated. The concentrate was chro:rratographed over silica
gel (50 g) and elution with ether yielded the cyanohydrin derivative
(986 mg, 49%) (mp 268-70°C): ir 3380 cm-l (H-bonded OH), 2980 cm-l
· (C-H stretching) ,2220 cm-1 (C;;N).

Synthesis of

17~-cyano-ll,B

5-diene. (11)
- -

,17ft -dihydroxy-3-pyrrolidinoandrosta-3,

Compound -10 (1 g) was dissolved in 150·ml of anhydrous

tetrahydrofuran and reduced with lithium

tri-~-butoxyaluminium

hy-

dride ( 2 g) at room temperature for 26 hrs . The mixture was poured
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into 150 rnl of a dilute solution of acetic acid and allowed to stand
for 2 hrs.

The solution was extracted with ether and dried over

anhydrous Na2so 4 . The evaporation of solvent and crystallization
of the residue from acetone-ether yielded crystalline product (198 mg,
20%) (mp 230-235°C):
(C;N).

ir 3400-3200 cm-l (H-bonded OH), 2225 cm-l

Further crystallization of the residual syrupy material with

ether yielded 500 mg of the starting material.

Attempted Acid hydrolysis of

11.· - Compound 10 ( 500 mg) was added

to 1 ml of concentrated HCl and the mixture was heated on a steam
bath for 12 hrs.

After cooling and dilution with water ( 5 rnl), the

aqueous solution was extracted three times with chloroform and dried
over anhydrous sodium sulfate.

The evaporation of the sol vent gave solid mat-

erial (200 mg, 40%).

Their spectrum of this material showed H-bonded
carboxylic absorption between 3500-3200 cm-1 and a decrease in the

intensity of nitrile absorption which indicated that partial hydrolysis
of the

17-.!l~..:..cyano

group of compound 10 might have occurred.
.

..

-1

The appearance of carbonyl absorption between 161-10....:1630 em

indicated

that hydrolysis of the enamine group had occurred.

Attempted Base hydrolysis of 11... - The cyanohydrin ( 200 mg) was dissolved in 3 ml of 2% :rrethanolic KOH and allowed to stand for 48 hrs
at room temperature.

The solvent was removed in vacuo and the residue

was diluted with water (4 ml), acidified
five times with ether.

with~

HCl and extracted

The organic layer was washed with water and
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dried over anhydrous Na2so 4 . The evaporation of the solvent gave
syrupy material (50 w~, 40%) which was C~Jstallized with ether.
The ir spectrurr1 of this material (mp 190°C) showed hydroxyl absorption
at 3500 cm-l (non-bonded OH) and a decrease in the intensity of nitrile
absorption, indicating that partial hydrolysis of the 17-alpha-cyano
group might have occurred.

The appearance of carbonyl absorption

between 1640-1630 cm-l indicated that hydrolysis of the enamine group
had occurred.

BIOLOGICAL ACTIVrrY

The pharmacologic study of anti-inflammatory agents is a dynamic
and corrplicated research area.

Although the etiologies and mechanisms

of the pathophysiology of inflammatory diseases are not well understood,
the combined efforts of medicinal chemists, biochemists, and pharmacologists have produced a reasonable pattern of the inflammatory process
(Figure 8), involving a multiplicity of factors. 35
According to this pattern, it becomes apparent that one might
define all of those drugs which combat any part of the normal
flammatory response as

11

anti-inflammatories 11 •

in~

However, those drugs

which interfere with the secondary effects and chronic disease state
might also be called 11 antirheumatic 11 or 11 antiarthritic11 •
Glucocorticoids exert a suppressive effect on the response of
tissue to injury by maintaining a balance between vasoconstrictor
and vasodilator influences.

They help to maintain vascular integrity,

to increase capillary resistance, and to potentiate the vasoconstrictor
action of norepinephrine.

The mast cells, which liberate histamine

(a powerful vasodilator), show morphological changes and suppression
of secretory activity under the influence of glucocorticoids.
Glucocorticoids retard leukocyte accumulation at the site of injU,cy · and also inhibit diapedesis.

The resistance to infection

after glucocorticoid administration is decreased, probably due to an
inhibition of phagocytosis.
Glucocorticoid-induced regression of thymus tissue is very striking.
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DAMAGING AGENT(S)

r Ai1tigen-antibody reactions

/

Chemical-physical irritants
Lymphocyte-induced delayed hypersensitivity
Bacterial invasion
Traurra
Other

LOCAL REACTIONS

SYSTm•UC REACTIONS

Venular dilation
Slow venular flow (prostaglandins
release)
Increased blood viscosity
Erythrostasis
Platelet aggregation
Small molecular mediator(s) release
Thrombus formation
Fibrin accumulation
Sludge
Neutrophil and lymphocyte
accumulation
Phagocytosis of irritant and
dan:aged tissues
Leucocyte and platelet breakdown
Increased serum enzymes (LDH, SGOT,
ICDH)
Release of cytoplasmic and
lyosomal enzymes
Release of additional small
molecular mediators
More damage: more leaks
Mesenchymal cell proliferation
Proliferation/endothelial
hypertrophy
Circulatory insufficiency

Increased body terrpera.ture
Pain
Granulocytosis and lymphocytosis
Increased fibrinogen
Increased C-reactive protein
Increased a.lpha and beta globulins
Increased ~lpha-2-glycoproteins
Decreased albumin
Decreased serum iron
Increased serum copper
Increased mucoproteins
Increased glycoproteins
Increased pituitary-adrenal
function
Increased ~-globulin: if
irrnnunologic

J__
PROMJriVE AND CONTRIBUTORY?

~
CELL IlE1ml AND NECRosiS {,;("

PRarECTIVE AND INHIBITORY?
OVERALL

l

PROCESS·~

~

LEAKY MEMBRANES
Endothelial cells

FIGURE 8

RESI'TiilliON
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An

intact thymus is necessary for the establishment of lymphoid tissue

that is responsible for recognition of &!tigenicity &id effective
antibody production. 36 The corticosteroid effect on lymphoid tissue
is manifested by lymphopenia.

Glucocorticoids cause a marked decrease

in the weight of lymphoid tissue and a prompt fall in circulating
lymphocytes.
The systemic anti-inflammatory efficacy of steroids can be assayed37
by thymus involution, granuloma pouch, experimental poly-arthritis
(~cobacterium

adjuvant arthritis), carrageenin-induced edema, differential

blood counts, and many other tests.
While all of the above tests document useful antiinflammatory
activity (detecting aspirin-, phenylbutazone-, fenamate-, indomethacin-,
and corticosteroid-like compounds), only the thymus involution assay
can be considered specific for glucocorticoid-like activity.

Structure-

activity studies on the corticosteroids have indicated that a double
bond between carbons 4 and 5, a ketone group at the 3-position, an
oxygen function at carbon-11, and an alRha-ketol chain at carbon 17 are
important for glucocorticoid activity.

The profound effect of hydro-

cortisone analogues on the thymus gland and the well-defined structureactivity relationships 39 , 40 , 41 noted in Table III, indicate that the
thymus involution assay would be useful in ascertaining the efficacy
of steroids at a primary level.

Therefore, the dioxolone analogues

of hydrocortisone were screened for biologic activity by Professor M.H.
Malone and L. DeCato, Jr., utilizing the method of Stephenson. 38
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TABLE III
The Relationship Between Structural Alternations of Hydrocortisone and
Anti-inflammatory Activity, Based Upon 'lnymus Involution Assays.
Analogues

Anti-inflanmatory Activity

5,6 double bond
6 alpha, 9 alpha fluoro group
$;alpha, 16 alph~ methyl group
2 alph~, 1nethyl group
19-nor Derivative
17, 20, epoxylation
20-keto group reduction
16 alpha, 17 ~ha acetonide

OH

0

4

Hydrocortisone Molecule
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METHOD OF THE THYMUS INVOLUTION ASSAY Male Sprague-Dawley rats (25 to 30 days old) obtained from Horton's
Laboratories, Oakland, California, were kept on Purina Laboratory Chow
and tap water ad libitum before and during the assay procedure.

All

drugs were dissolved or suspended in Mazola com oil and administered

subcutaneously in the back at a dosage volume of 0. 2 ml/100 g.

The

compounds were given every 8 hours for six doses utilizing 0.25 ml
precision grade syringes and 25 gauge 5/8-inch needles.

The animals

were sacrificed 24 hours after the last injection by decapitation
and exsanguination.

Thymus and adrenal glands were removed by blunt

dissection and carefully cleaned of all extraneous connective tissue
and fat and weighed on an Ainsworth balance (type 10) to the nearest
0.1 mg.

Gland weights were calculated as mg/100 g final body weight

± standard

error.

Results are presented in Table IV.

Since adrenal weights are also markedly influenced by exogeneous
glucocorticoids, the collection of adrenal weights was done so as to
either support or to refute the conclusions based upon thymus involution.
Levels of significance between treatments in Table IV wer,e~ calculated
using analysis of variance techniques following the procedures of
Bliss and Calhoun. 42
ASSAY RESULTS Both dosage levels of the isopropylidene derivative
17$-acid or

C.i)

of the

(4'R)-spiro[ll~-hydroxyandrost-4-en-3-one-17,4'-(2',2'

dimethyl-11 ,3'-dioxolan-5'-one)] showed a slight decrease in the thymus
weight but .this change was not statistically significant.

With the

TABLE IV
Thymus, Adrenal and Body Weight of the Male Sprague-Daw1ey Rats Twenty-Four

After a Two-Day Treatment wifh-·Hydrocort:Lsone ~d · 3 ?i:J,d · '4 ..··,.

Subcutaneous
Drug Treatment

Dosage,
mg./kg. a

Vehicle Control
Hydrocortisane

Thymus Weight,
mg./100g.
body weight

Total Body Weight, g.
Pre-Treatment
Post-Treatment

Q.

29.7

± 1. 8

66.2

± 1.4

80.2

± 2.0

279-9 ± 16.0
( <O.OOl) c

22 .. 1

± 1.5

65.5

± 2.4

78.8

± 2.6

67.6

± 2.2

78.8;!; 2.3
( )0.5)

403.7
6.0

Adrenal Weight,
mg./100 g.
body weight

± 13.8

(< 0.01)

(>0. 5)

(>0. 5)

12.0

231.4

± 11.3

20.8 ± Ow9
C<o.ool)

l

12.0

402.0

± 17.9

26.0

± 1.6

(:> 0 .1)

67.7 ± 1.8
( )0 .5)

82.6 ± 2.6
( )0.5)

l

96.0

353-5

± 15.5

24.7 ± 0.8
((0.05)

66.2 ± 2.1
( )0 .5)

80.6 ± 2.6
(>0.5)

4

12.0

399.6

±

21.5 ± 1.4
C<O.Ol)

66.6 ± 1.8
( )0. 5)

81.7

4

96.0

373.4

± 13.8

25.4

Hydrocortisone

(<0.001)
(>0.5)

(< 0.05)

9 ..4
C"} 0 .5)

(>0.1)

± 1.5

(>0. 05)

(>O .5)

66.7

± 2:~2

(>0 .5)

± 3.1

(>0. 5)

.80.1 +
- 2.3
()0.5)

a
-

Total dosage, fractionally divided into six doses administered every eight hours (2 ml./kg.) in corn oil
vehicle.

b

All results listed as the mean ±1 standard error (10 rats/treatment).

c

Figures within parentheses indicate the observed value of p.
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lower dosage there was a significant decrease in adrenal weight, but
this was not seen at the higher dosage.

Pharmacologically this effect

is not easily explainable (normally the high dose should have produced
a fUrther dose-response in adrenal weight).
The compound]_ or (4 1 R)-spiro[lH8-hydroxyandrost-4-en-3-one-17,4'(l'-3'-dioxolan-5'-one)] had significant thymic involuting activity
at the highest dosage activity used which was supported by a significant
decrease in adrenal weight.

These effects were less

pr~nounced

than

those produced by hydrocortisone at a cumulative dosage of only
6 mg/kg.

From these results, it can be concluded that both of the dioxolonetype analogues of hydrocortisone under study were less potent than
hydrocortisone (]_ having ~ 0 . 06 x the potency of hydrocortisone on
a mg/kg basis).

Neither ]_nor

i

appear to possess clinically us:ful

anti-inflammatory potential considering the relatively high dosage
levels utilized in this animal study.

CONCLUSIONS

The stereochemistry of hydrocortisone is fixed by virtue of its
tetracyclic fused ring system.

However, its C-17 ketal group is capable

of assuming different conformations due to the C-17/C-20 and C-20/
C-21 rotamers.

As one objective of these studies we have synthesized

dioxolone derivatives of ll./3, 175,-dihydroxyandrost-4-en-3-one-17~
carboxylic acid as conformationally rigid models of the low-energy
conformer of hydrocortisone.

He also undertook the synthesis of

the epimeric dioxolone derivative of 11/}, 17~-dihydroxyandrost4-en-3-one-17c:i-carboxylic acid as a possible model for a high-energy
conformer of hydrocortisone.

It was hoped that a

con~arison

of the

anti-inflanmatory activities of these derivatives would reveal some
conformational specificity for the hydrocortisone receptors.

Un-

fortunately, the attenpted synthesis of the epimeric dioxolone derivative
was not successful.

Therefore, it was not possible to draw any con.:..

elusions with respect to conformational specificity.
As another objective of these studies we hoped to test the hypothesis
that the C-17 ketal group of hydrocortisone serves primarily as a hydrogenbridge donor when it interacts with its receptor.

The relatively

weak anti-inflanmatory potential of the low-energy models of hydrocortisone (].. and

~)

as measured by thymus involution assay tends to

support this hypothesis.

Apparently none of the oxygen functions in

45

the dioxolone rings of these model compounds can serve as hydrogenbridge donors.
We suggest that further studies should be undertaken with the
objectives of designing more suitable models for the high-energy
conformers of hydrocortisone so that comparisons of anti-inflammato1~
activities can be made.

Also, it should be of interest to compare the

plasma protein binding affinities of these model compounds with those
of the corticosteroids which were investigated by Eger et a1. 18
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APPENDIX.

1.
2.

3.
4.
5.
6.

7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.

Acetone (reagent grade)
Acetic acid 99.7% (reagent, Dupont)
Acetone cyanohydrln (reagent, Aldrich)
Androst-14-en-3,11,17-trione (Sigma)
Benzene (reagent grade, Baker)
Chloroform (reagent grade, l\1CB)
Dimethoxymethane (reagent grade , Aldri.ch)
Dioxm1e (reagent grade, Aldrich)
Ether (reagent grade, Baker)
Ethylacetate (reagent grade, Baker)
Hydrocortisone (Sigma)
1-hydroxycyclopentane carboxylic acid (reagent grade, Aldrich)
Hydrochloric acid 36.5% (reagent, Dupont)
Isopropanol (reagent grade, Baker)
Lithium-tri-t-butoxyaluminium hydride (reagent grade, Aldrich)
Methanol (anhydrous, l\1erck)
Methylene chloride (reagent grade, Baker)
Paraforrnaldehyde (reagent, Eastman)
Perchloric Acid 70% (Baker)
Periodic acid (reagent, Sigma)
Potassium hydroxide (Analyzed reagent grade, Bllicer)
Pyridine (Analyzed reagent grade, Baker)
Pyrrolidine (Analyzed reagent grade, Baker)
Silicagel (Analyzed reagent grade, Baker)
Sodium bicarbonate (Analyzed reagent grade, Baker)
Sodium borohydride 99% pure (Delmar)
Sodium Sulfate, ffi1hydrous (Baker)
Tetrahydrofuran (Analyzed reagent grade, Aldrich)
Trifluoroill2thanesulphonic acid (reagent, Pierce Chemicals)

